Skip to main content

CALGB 30601: A phase II study of dasatinib (D) in patients (pts) with previously treated malignant mesothelioma (MM).

Publication ,  Journal Article
Dudek, A; Pang, H; Kratzke, RA; Otterson, GA; Vokes, EE; Kindler, HL
Published in: Journal of Clinical Oncology
May 20, 2010

Duke Scholars

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2010

Volume

28

Issue

15_suppl

Start / End Page

7037 / 7037

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Dudek, A., Pang, H., Kratzke, R. A., Otterson, G. A., Vokes, E. E., & Kindler, H. L. (2010). CALGB 30601: A phase II study of dasatinib (D) in patients (pts) with previously treated malignant mesothelioma (MM). Journal of Clinical Oncology, 28(15_suppl), 7037–7037. https://doi.org/10.1200/jco.2010.28.15_suppl.7037
Dudek, A., H. Pang, R. A. Kratzke, G. A. Otterson, E. E. Vokes, and H. L. Kindler. “CALGB 30601: A phase II study of dasatinib (D) in patients (pts) with previously treated malignant mesothelioma (MM).Journal of Clinical Oncology 28, no. 15_suppl (May 20, 2010): 7037–7037. https://doi.org/10.1200/jco.2010.28.15_suppl.7037.
Dudek A, Pang H, Kratzke RA, Otterson GA, Vokes EE, Kindler HL. CALGB 30601: A phase II study of dasatinib (D) in patients (pts) with previously treated malignant mesothelioma (MM). Journal of Clinical Oncology. 2010 May 20;28(15_suppl):7037–7037.
Dudek, A., et al. “CALGB 30601: A phase II study of dasatinib (D) in patients (pts) with previously treated malignant mesothelioma (MM).Journal of Clinical Oncology, vol. 28, no. 15_suppl, American Society of Clinical Oncology (ASCO), May 2010, pp. 7037–7037. Crossref, doi:10.1200/jco.2010.28.15_suppl.7037.
Dudek A, Pang H, Kratzke RA, Otterson GA, Vokes EE, Kindler HL. CALGB 30601: A phase II study of dasatinib (D) in patients (pts) with previously treated malignant mesothelioma (MM). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010 May 20;28(15_suppl):7037–7037.

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2010

Volume

28

Issue

15_suppl

Start / End Page

7037 / 7037

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences